Entecavir and tenofovir reduce hepatitis B virus-related hepatocellular carcinoma recurrence more effectively than other antivirals

Journal of Viral Hepatitis Apr 16, 2018

Cho H, et al. - Researchers determined whether or not high-potency Nucleos(t)ide analogues (NAs) (entecavir and tenofovir disoproxil fumarate [TDF]) reduce the risk of tumour recurrence more potently than low-potency NAs after curative treatment of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). They noted that antiviral agents with high genetic barrier to resistance (entecavir and TDF) reduced the risk of HCC recurrence compared with other antivirals and no antiviral treatment. This was particularly evident in patients with high baseline viral load.
Go to Original
Non loggedin lock

To read this article Sign up / Login for free

This article is only available to members. Are you a doctor? Click here to signup for free.
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen